Review Article

Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplastic Drugs

Vilma Maldonado Lagunas¹ and Jorge Meléndez-Zajgla²

¹ Laboratorio de Biología Molecular, Subdirección de Investigación Básica, Instituto Nacional de Cancerológica, Avenida San Fernando 22, 14080 Tlalpan, Mexico
² Genómica Funcional de Cáncer de Laboratorio, Instituto Nacional de Medicina Genómica, 03020 Mexico City, Mexico

Correspondence should be addressed to Vilma Maldonado Lagunas, vilmaml@gmail.com

Received 12 July 2007; Accepted 18 December 2007

Platinum drugs continue to be major chemotherapy drugs for cancer treatment. Nevertheless, acquired or intrinsic resistance to these compounds is common in human tumors. One important mechanism for this resistance is the avoidance of cells entering the apoptotic pathway. Nuclear factor-kappa B (NF-kappa B, NF-κB) is a pleiotropic transcription factor key in determining the death threshold of human cells. This factor is important in the final response of cells to platinum drugs, as exemplified by in vitro and in vivo models showing that inhibition of NF-κB can sensitize cancer cells to the effects of these drugs. New approaches focusing on the inhibition of NF-κB could help to minimize or even eliminate intrinsic or acquired resistance to platinum drugs.

Copyright © 2008 V. M. Lagunas and J. Meléndez-Zajgla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Cis-diaminedichloroplatinum (II), first known as Peyrone’s salt, was synthesized in 1844 by the Italian doctor, Michele Peyrone [1]. Fifty years later, Alfred Werner “the Father of Coordination Chemistry” elucidated its structure [2]. This inorganic compound now known as cisplatin or CDDP is a neutral complex, Pt(NH₃)₂Cl₂, with a central platinum atom (Pt), two chloride atoms (Cl⁻), and two molecules of ammonia (see Figure 1). In 1965, American chemist Rosenberg et al., in Michigan State University, found that electrolysis with platinum electrodes inhibits the growth of Escherichia coli bacteria. This research group determined that platinum oxidized by electrolysis to Pt⁺² reacts with sodium chloride and ammonium salts in the bacterial growth media, forming cisplatin [3]. Due to the ability of cisplatin to inhibit cell division, Rosenberg analyzed its possible anticancer properties and found that, indeed, this compound inhibited the growth of sarcomas transplanted into rats. Nowadays, cisplatin has become one of the major chemotherapy drugs [4].

2. CISPLATIN MECHANISM OF ACTION

Cisplatin enters the cell mainly by passive diffusion, although its efflux and uptake have been linked to copper metabolic pathways, implicating the high-affinity cooper transporter (CTR1) and the copper-transporting P-type adenosine triphosphatase (ATP-7B) [5, 6]. Once inside the cell, cisplatin forms adducts with DNA with a preference for nucleosomal regions. In this process, cisplatin loses one of its chloride ions and binds a molecule of water in order to attach to the nitrogen-7 position of a DNA purine. Subsequently, the other chloride is replaced by another molecule of water, thereby binding to DNA in a covalent form to produce 1, 2 or 1, 3 intrastrand or interstrand cross-links. Cisplatin also forms simple monoadducts with DNA, or monoadducts that bind also to proteins or glutathione molecules (see Figure 2) [7, 8]. The importance of this molecular mechanism is highlighted by the reports showing that the level of platinum-DNA adducts correlates with clinical response of cisplatin [9, 10].

DNA damage produced by cisplatin is detected and repaired by the nucleotide excision pathway (NER) [11, 12]. This pathway involves two subpathways; transcription-coupled NER and global genomic NER. Furuta et al. [12] reported that transcription-coupled NER-deficient cells are hypersensitive to cisplatin, irrespective of their global genomic NER status, showing that the former pathway could be responsible for resistance to the platinum drug. If the damage produced by cisplatin is not totally repaired, cells emit
signals to initiate cellular death through apoptosis or necrosis, depending on the particular cisplatin concentration and specific tissue involved [13].

Several signal transduction pathways are activated in the cell after exposure of cisplatin, including the 3 main subfamilies of MAPK kinases, namely, extracellular signal-regulated kinase (ERK) [14], c-Jun NH2-terminal kinase (JNK) [15, 16], and p38 mitogen-activated protein kinase (p38 MAPK) [17, 18]. Cisplatin also activates v-akt murine thymoma viral oncogene homologue (AKT) [19, 20] and nuclear factor-kappa B (NF-κB) pathways [21, 22].

3. NF-KAPPA B TRANSDUCTION PATHWAY

NF-κB is a family of transcription factors constituted by 15 dimers that result from different combinations of 5 proteins (Rel (cRel), Rel A (p65), Rel B, NFKB-1 (p105/p50), and NFKB-2 (p100/p52)). Each of these subunits contains a 300-amino acid Rel homology (RH) domain, which has the ability to bind to a defined DNA sequence (see Figure 3) [23]. These dimers regulate the expression of hundreds of genes involved in immune and inflammatory response, proliferation, differentiation, and cell survival. However, examples are also known where NF-κB functions as a proapoptotic factor. The control over cell survival is achieved mainly through up-regulation of the antiapoptotic proteins, cIAP1, cIAP2, XIAP, Bfl/A1, BCL-xL, and FLIP, whereas the proapoptotic activity is mediated by FAS, FASL, DR4, and DR5 genes [24]. Although not universal, it seems that the antiapoptotic functions of NF-κB are mediated by dimers containing the relA subunit of this transcriptional factor.

One critical step in the control of NF-κB activity is the association of these dimers with members of the inhibitor of kappa B family (Ikappa-B alpha, Ikappa-B beta, Ikappa-B epsilon, p105/gamma, p100/delta, and BCL3). The union of a particular dimer with one Ikappa-B molecule prevents its nuclear translocation. NF-κB subunits can be released from its inhibitor by specific posttranslational processes, such as phosphorylation or ubiquitination followed by proteosome-mediated proteolysis (see Figure 4).

The most studied upstream activator of NF-κB is the inhibitor of kappa B kinase (IKK) complex. This complex contains two kinase catalytic subunits, IKK alpha and IKK beta, as well as a helical subunit termed IKK gamma (NEMO) which plays a critical role in the assembly of the IKK complex. Both catalytic kinase subunits are highly homologous, but are activated by different stimuli. Once activated with proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) or interleukin-1β (IL-1β), IKK β inactivates Ikappa-B-α, Ikappa-B-β, and Ikappa-B-ε, inducing the so-called canonical NF-κB pathway, described previously. IKK-α is activated by more diverse stimuli, such as CD40, lymphotixin β, or lipopolysaccharide, which induce processing of the p52 precursor protein, p100, forming homo- or heterodimers with p50 to constitute the noncanonical NF-κB pathway [25].

4. NF-KAPPA B AND CISPLATIN RESISTANCE

Platinum drug resistance can be mediated by several mechanisms, such as drug inactivation, cellular drug efflux, alterations in drug target, modulation of DNA repair, and evasion from apoptotic cell death [13, 26].

Due to the importance of NF-κB in determining the final outcome of an apoptotic insult and the fact that most cancer cells present a constitutive activation of this transcription factor, it is not unexpected that it could be involved in resistance to platinum drugs. Earlier reports showed that cisplatin is able to induce activation of NF-κB [22, 27], thereby providing a mechanism of intrinsic resistance. Furthermore, low-dose gamma irradiation induces a crossresistant phenotype in HeLa cells, which is associated with NF-κB activation by a deregulation of silencer of death domain (SODD) protein expression [28]. NF-κB activation after cisplatin exposure seems to be a widespread phenomenon in cancer [29] and normal cells [30]. However, cisplatin exposure results in downregulation of NF-κB activity in hepatoma cells [31] although the reason for this remains unclear. Tissue-specific differences could play a role since mice lacking p65 subunit die at 15 days of gestation by massive liver cell apoptosis, showing a particular and specific requirement for the NF-κB antiapoptotic function, specifically in liver homeostasis [32]. Alternatively, the well-known negative feedback mediated by Ikappa B synthesis, which downregulates NF-κB activity after an initial stimulus, could explain this contradiction [33]. Further complicating this situation, different combinations of NF-κ subunits are known to have opposing transcriptional activities, which could help explain the contradictory results. In addition, cancer cells with cisplatin-resistant phenotypes have elevated NF-κB activity [21, 34] although the molecular reason behind this activation remains obscure.

Supporting the relevance of NF-κB importance in the control of apoptosis induced by cisplatin is that its inhibition by different methods sensitizes cancer cells to the drug. Genistein, a soy isoflavonoid with NF-κB-inhibiting properties, potentiates cisplatin effects on pancreatic cancer cells [35]. Similarly, inhibition of NF-κB translocation or activation increased the efficacy of cisplatin on an in vivo model of ovarian cancer [21] and on cultured head and neck [36], metal-based drugs...
made ovarian cancer patients more sensitive to carboplatin [42]. Similarly, preclinical studies demonstrated that the newly synthesized NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), enhanced the sensitivity of YCU-H and KB cells to cisplatin [36]. Furthermore, the importance of NF-κB in resistance can be found in the blocking of its activation by an adenovirus carrying a "superresponder" form of I-κB (ad-IkappaBalpha) in cisplatin-resistant lung cancer cells, which restored their sensitivity to control levels found in sensitive cell lines [43]. These results warrant further exploration of the possible clinical use of NF-κB inhibitors in patients with intrinsic or acquired platinum drug-resistant cancers.

5. MECHANISMS OF NF-KAPPA B ACTIVATION BY CISPLATIN

After DNA damage, several transduction cascades are activated, among them JNK and p38 [16]. Activation of JNK takes place via the MEKK1/SEK1 cascade required for cell death after platinum drug exposure [44]. MEKK1 activation drives the activation of NF-κB, seen after cisplatin treatment [45], providing a basis for a possible mechanism of acquired resistance. On the other hand, Yeh et al. [46] demonstrated that the MEK/ERK pathway is one of the NF-κB inhibitory circuits activated after exposure of cervical cancer cells to cisplatin. This mechanism relies on the alteration of the phosphorylation of p65 by protein phosphatase-4 [46].
These cascades activate the phosphorylation, ubiquitination, and degradation of NF-κB inhibitor I-κB, allowing translocation of active NF-κB dimers into the nucleus [22], providing a plausible basis for intrinsic or acquired resistance, as previously discussed.

6. DOWNSTREAM TARGETS OF NF-KAPPA B

As mentioned above, NF-κB is a pleiotropic transcription factor with target genes involved in several cellular processes. At least 20 proteins involved in the regulation of apoptosis present kappa-B consensus sites in their promoters and are actively regulated by this transcription factor [47]. Although no comprehensive study of the NF-kappa B-responsive genes involved in cisplatin resistance has been published, recent reports indicate that Bfl-1/A1 [48] and c-Myc [49] could be 2 of these genes, but clearly more investigations are needed.

7. NEW PLATINUM COMPOUNDS

After the initial discovery of cisplatin, several analogs have been synthesized with the purpose of improving their antineoplastic activity and reducing adverse effects such as nephrotoxicity. One of the successful analogs is carboplatin, which contains a platinum atom surrounded with two ammonia groups and two other ligands in a ring structure. Carboplatin appears to be superior to cisplatin in terms of therapeutic effectiveness for some tumors such as germ cell tumors, bladder cancer, as well as head and neck cancer, while in others (e.g., lung and ovarian cancer), their efficacies are comparable [50]. Carboplatin treatment downregulates constitutive NF-κB activity and prevents nuclear retention of p65 in liver cancer [51] and glioma cell lines [52].

Oxaliplatin is another cisplatin analog that contains a platinum atom complexed with 1,2-diaminocyclohexane that has an oxalate ligand. Its spectrum of activity and mechanism of action and resistance are different from cisplatin and carboplatin [53]. Downregulation of NF-κB transactivation by pharmacological inhibitors enhances oxaliplatin cytotoxicity in a panel of 4 colon adenocarcinoma cell lines [54].

Recent work has been the synthesis of water-soluble platinum complexes that can be absorbed after oral administration, such as JM216 and its metabolite JM118 [55], which have demonstrable oral antitumor activity in mice broadly equivalent to intravenously administered cisplatin and a toxicological profile similar to that of carboplatin. To date, there are no studies focusing on the activity of NF-κB in relation to these compounds.

A new promising approach is the encapsulation of cisplatin in sterically stabilized, long circulating, PEGylated liposomes, such as SPI-77, which show more stability in plasma and have a longer circulation time, greater efficacy, and lower toxicity than free cisplatin. Similar to this compound is lipoplatin, which is formed from cisplatin and liposomes composed of dipalmitoyl phosphatidyl glycerol (DPPG), soy phosphatidyl choline (SPC-3), cholesterol, and methoxy-polyethylene glycol-distearoyl phosphatidylethanolamine (mPEG2000-DSPE) [56, 57]. There are no studies to date on the routes that activate these new drugs.

8. CONCLUSION

In order to increase the benefit of current platinum-based drugs and to direct effort to obtain improved agents, it is of great importance to understand the molecular basis of
acquired and intrinsic resistance. NF-κB is a key to this understanding due to its importance in determining the final cell response to platinum drugs. New approaches focusing in the inhibition of this factor could help to minimize or even eliminate resistance to platinum drugs or to provide drugs with less systemic toxicity.

REFERENCES

[1] M. Peyrone, “Ueber die einwirkung des ammoniak auf plat-inchlorur,” Annalen der Chemie und Pharmacie, vol. 51, no. 1, pp. 1–29, 1844.

[2] K. Chvalová, V. Brabec, and J. Kaspárková, “Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin,” Nucleic Acids Research, vol. 35, no. 6, pp. 1812–1821, 2007.

[3] B. Rosenberg, L. Van Camp, and T. Krigas, “Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode,” Nature, vol. 205, no. 4972, pp. 698–699, 1965.

[4] B. Rosenberg, “Platinum coordination complexes in cancer chemotherapy,” Naturwissenschaften, vol. 60, no. 9, pp. 399–406, 1973.

[5] S. Ishida, J. Lee, D. J. Thiele, and I. Herskowitz, “Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctrl1 in yeast and mammals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14298–14302, 2002.

[6] M. T. Kuo, H. H. W. Chen, L.-S. Song, N. Savoraj, and T. Ishikawa, “The roles of copper transporters in cisplatin resistance,” Cancer and Metastasis Reviews, vol. 26, no. 1, pp. 71–83, 2007.

[7] G. Laurent, L. C. Erickson, N. A. Sharkey, and K. W. Kohn, “DNA cross-linking and cytotoxicity induced by cis-diaminedichloroplatinum(II) in human normal and tumor cell lines,” Cancer Research, vol. 41, pp. 3347–3351, 1981.

[8] K. Chvalová, V. Brabec, and J. Kaspárková, “Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin,” Nucleic Acids Research, vol. 35, no. 6, pp. 1812–1821, 2007.

[9] L. Martelli, F. Di Mario, P. Botti, E. Ragazzi, M. Martelli, and L. Kelland, “Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status,” Biochemical Pharmacology, vol. 74, no. 1, pp. 20–27, 2007.

[10] V. Brabec and J. Kasparkova, “Modifications of DNA by platinum complexes related to resistance of tumors to platinum antitumor drugs,” Drug Resistance Updates, vol. 8, no. 3, pp. 131–146, 2005.

[11] I. Husain, S. G. Chaney, and A. Sancar, “Repair of cisplatin-DNA adducts by ABC excinuclease in vivo and in vitro,” Journal of Bacteriology, vol. 163, no. 3, pp. 817–823, 1985.

[12] T. Furuta, T. Ueda, G. Aune, A. Sarasin, K. H. Kraemer, and Y. Pommier, “Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells,” Cancer Research, vol. 62, no. 17, pp. 4899–4902, 2002.

[13] V. Maldonado, J. Melendez, H. Gonzalez, and A. Ortega, “Internucleosomal DNA cleavage in HeLa cells exposed to cisplatin,” Biochemistry and Molecular Biology International, vol. 37, no. 4, pp. 691–696, 1995.

[14] Y. K. Kim, H. J. Kim, C. H. Kwon, et al., “Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells,” Journal of Applied Toxicology, vol. 25, no. 5, pp. 374–382, 2005.

[15] B. W. Zanke, K. Boudreau, E. Rubie, et al., “The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat,” Current Biology, vol. 6, no. 5, pp. 606–613, 1996.

[16] I. Sánchez-Pérez, M. Martínez-Gomariz, D. Williams, S. M. Keyse, and R. Perona, “CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin,” Oncogene, vol. 19, no. 45, pp. 5142–5152, 2000.

[17] P. Bragado, A. Armesilla, A. Silva, and A. Porras, “Apoptosis by cisplatin requires p53 mediated p38a MAPK activation through ROS generation,” Apoptosis, vol. 12, no. 9, pp. 1733–1742, 2007.

[18] P. Pandey, J. Raisingaud, M. Kaneki, et al., “Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms,” Journal of Biological Chemistry, vol. 271, no. 39, pp. 23775–23779, 1996.

[19] Y. Mitsuuchi, S. W. Johnson, M. Selvakumaran, S. J. Williams, T. C. Hamilton, and J. R. Testa, “The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21\textsuperscript{WAF1/CIP1} induced by cisplatin and paclitaxel,” Cancer Research, vol. 60, no. 19, pp. 5390–5394, 2000.

[20] D. Wang and S. J. Lippard, “Cellular processing of platinum antitumor drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 307–320, 2005.

[21] S. Mabuchi, M. Ohmichi, Y. Nishio, et al., “Inhibition of NF-κB increases the efficacy of cisplatin in vitro and in vivo ovarian cancer models,” Journal of Biological Chemistry, vol. 279, no. 22, pp. 23477–23485, 2004.

[22] V. Maldonado, J. Meléndez-Zaigla, and A. Ortega, “Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 381, no. 1, pp. 67–75, 1997.

[23] A. Hoffmann, G. Natoli, and G. Ghosh, “Transcriptional regulation via the NF-κB signaling module,” Oncogene, vol. 25, no. 51, pp. 6706–6716, 2006.

[24] E. Burstein and C. S. Duckett, “Dying for NF-κB? Control of cell death by transcriptional regulation of the apoptotic machinery,” Current Opinion in Cell Biology, vol. 15, no. 6, pp. 732–737, 2003.

[25] R. B. Marienfeld, L. Palkowitsch, and S. Ghosh, “Dimerization of the IκB kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF-κB activity,” Molecular and Cellular Biology, vol. 26, no. 24, pp. 9209–9219, 2006.

[26] M. A. Barry, C. A. Behnke, and A. Eastman, “Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia,” Biochemical Pharmacology, vol. 40, no. 10, pp. 2353–2362, 1990.

[27] A. Dodi and R. A. K. Singh, “Mechanism of NF-κB translocation in macrophages treated in vitro with cisplatin,” Immunology Letters, vol. 63, no. 1, pp. 9–17, 1998.

[28] H. Eichholz-Wirth and D. Sagan, “IκB/NF-κB mediated cisplatin resistance in HeLa cells after low-dose γ-irradiation is associated with altered SODD expression,” Apoptosis, vol. 5, no. 3, pp. 255–263, 2000.

[29] S.-E. Chuang, P.-Y. Yeh, Y.-S. Lu, et al., “Basal levels and patterns of antitumor drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells,” Biochemical Pharmacology, vol. 63, no. 9, pp. 1709–1716, 2002.

[30] H. D. C. Francescato, R. S. Costa, C. Scavone, and T. M. Coimbra, “Parthenolide reduces cisplatin-induced renal damage,” Toxology, vol. 230, no. 1, pp. 64–75, 2007.
[31] J. S. Kim, J. M. Lee, Y.-J. Chwae, et al., “Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways,” *Biochemical Pharmacology*, vol. 67, no. 8, pp. 1459–1468, 2004.

[32] A. A. Beg, W. C. Sha, R. T. Bronson, S. Ghosh, and D. Baltimore, “Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kB,” *Nature*, vol. 376, no. 6536, pp. 167–170, 1995.

[33] P. J. Chiao, S. Miyamoto, and I. M. Verma, “Autoregulation of IκBα activity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 1, pp. 28–32, 1994.

[34] T. Kato, D. C. Duffey, F. G. Ondrey, et al., “Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kB,” *Head & Neck*, vol. 22, no. 8, pp. 748–759, 2000.

[35] M. E. O’Brien, H. Anderson, E. Kaukel, et al., “SRL 172 (killed *Mycobacterium vaccae*) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results,” *Annals of Oncology*, vol. 15, no. 6, pp. 906–914, 2004.

[36] H.-Y. Ruan, M. Masuda, A. Ito, et al., “Effects of a novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines,” *Head & Neck*, vol. 28, no. 2, pp. 158–165, 2006.

[37] K. Tozawa, T. Okamoto, Y. Hayashi, S. Sasaki, N. Kawai, and K. Kohri, “N-acetyl-L-cysteine enhances chemotherapeutic effect on prostate cancer cells,” *Urological Research*, vol. 30, no. 1, pp. 53–58, 2002.

[38] M. M. Abdel-Latif, A. A. Raouf, K. Sabra, D. Kelleher, and J. V. Reynolds, “Vitamin C enhances chemosensitization of esophageal cancer cells in vitro,” *Journal of Chemotherapy*, vol. 17, no. 5, pp. 539–549, 2005.

[39] M. M. Abdel-Latif, J. M. O’Riordan, N. Ravi, D. Kelleher, and J. V. Reynolds, “Activated nuclear factor-kB and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy,” *Diseases of the Esophagus*, vol. 18, no. 4, pp. 246–252, 2005.

[40] P. Y. Yeh, S.-E. Chuang, K.-H. Yeh, Y. C. Song, and A.-L. Cheng, “Involvement of nuclear transcription factor-kB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells,” *Biochemical Pharmacology*, vol. 66, no. 1, pp. 25–33, 2003.

[41] H. Eichholtz-Wirth and K. Marx, “Clonal variability of radiation-induced cisplatin resistant HeLa cells,” *Anticancer Research*, vol. 18, pp. 2989–2991, 1998.

[42] C. Aghajanian, “Clinical update: novel targets in gynecologic malignancies,” *Seminars in Oncology*, vol. 31, 16, pp. 22–26, 2004.

[43] C. T. Lee, J. Y. Seol, S. Y. Lee, et al., “The effect of adenovirus-β-galactosidase transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diaminedichloro-platinum(II)/(cisplatin) and doxorubicin(adriamycin),” *Lung Cancer*, vol. 41, no. 2, pp. 199–206, 2003.

[44] I. Sánchez-Pérez and R. Perona, “Lack of c-Jun activity increases survival to cisplatin,” *FEBS Letters*, vol. 453, no. 1-2, pp. 151–158, 1999.

[45] I. Sánchez-Pérez, S. A. Benitah, M. Martínez-Gomariz, J. C. Lacal, and R. Perona, “Cell stress and MEK1-mediated c-Jun activation modulate NFκB activity and cell viability,” *Molecular Biology of the Cell*, vol. 13, no. 8, pp. 2933–2945, 2002.

[46] P. Y. Yeh, K.-H. Yeh, S.-E. Chuang, Y. C. Song, and A.-L. Cheng, “Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kB activation by protein phosphatase 4-mediated NF-kB p65 Thr dephosphorylation,” *Journal of Biological Chemistry*, vol. 279, no. 25, pp. 26143–26148, 2004.

[47] H. L. Pahl, “Activators and target genes of Rel/NF-kB transcription factors,” *Oncogene*, vol. 18, no. 49, pp. 6853–6864, 1999.

[48] J. K. Kim, K. D. Kim, E. Lee, et al., “Up-regulation of Bfl-1/A1 via NF-kB activation in cisplatin-resistant human bladder cancer cell line,” *Cancer Letters*, vol. 212, no. 1, pp. 61–70, 2004.

[49] J. K. Park, Y. M. Chung, S. Kang, et al., “c-Myc exerts a protective function through ornithine decarboxylase against cellular insults,” *Molecular Pharmacology*, vol. 62, no. 6, pp. 1400–1408, 2002.

[50] J. Lekich and N. Anderson, “Carboplatin versus cisplatin in solid tumors: an analysis of the literature,” *Annals of Oncology*, vol. 9, no. 1, pp. 13–21, 1998.

[51] S. Singh and M. K. Bhat, “Carboplatin induces apoptotic cell death through downregulation of constitutively active nuclear factor-kB in human HPV-18 E6-positive HEp-2 cells,” *Biochemical and Biophysical Research Communications*, vol. 318, no. 2, pp. 346–353, 2004.

[52] K. D. Weaver, S. Yee, J. C. Cusack Jr., A. S. Baldwin Jr., and M. G. Ewend, “Potentiation of chemotherapeutic agents following antagonism of nuclear factor-kB in human gliomas,” *Journal of Neuro-Oncology*, vol. 61, no. 3, pp. 187–196, 2003.

[53] E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic, “Cellular and molecular pharmacology of oxaliplatin,” *Molecular Cancer Therapeutics*, vol. 1, no. 3, pp. 227–235, 2002.

[54] T. V. Rakitina, I. A. Vasilievskaya, and P. J. O’Dwyer, “Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kB signaling,” *Cancer Research*, vol. 63, no. 24, pp. 8600–8605, 2003.

[55] E. Fokkema, H. J. M. Groen, M. N. Helder, E. G. E. de Vries, and C. Meijer, “JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin,” *Biochemical Pharmacology*, vol. 63, no. 11, pp. 1989–1996, 2002.

[56] J. M. Meerum Terwogt, G. Groenewegen, D. Pluim, et al., “Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin,” *Cancer Chemotherapy and Pharmacology*, vol. 49, no. 3, pp. 201–210, 2002.

[57] G. P. Stathopoulos, T. Bounikas, M. Vougiouka, et al., “Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study,” *Oncology Reports*, vol. 13, no. 4, pp. 589–595, 2005.